FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2578102513> ?p ?o ?g. }

• W2578102513 endingPage "293" @default.
• W2578102513 startingPage "286" @default.
• W2578102513 abstract "Our aims were to determine if targeting protein for Xklp2 (TPX2) is correlated with clear cell renal cell carcinoma (ccRCC) histology and oncologic outcomes using The Cancer Genome Atlas (TCGA) and an institutional tissue microarray (TMA). Clinicopathological data obtained from the TCGA consisted of 415 samples diagnosed with ccRCC. A TMA was constructed from tumors of 207 patients who underwent radical nephrectomy for ccRCC. TPX2 expression by immunohistochemistry on TMA was assessed by a genitourinary pathologist. Clinical data were extracted and linked to TMA cores. TPX2 and Aurora-A mRNA coexpression were evaluated in the TCGA cohort. Overall survival (OS), cancer-specific survival, and recurrence-free survival (RFS) were analyzed using the Kaplan-Meier method and log-rank statistics. Univariate and multivariate analyses were conducted using Cox proportional hazard models. Median follow-up time for the TCGA cohort was 3.07 years. Aurora-A and TPX2 mRNA coexpression were significantly correlated (Pearson correlation = 0.918). High TPX2 mRNA expression was associated with advanced stage, metastasis, poor OS, and RFS. Median follow-up time for the TMA cohort was 5.3 years. Elevated TPX2 protein expression, defined as greater than 75th percentile staining intensity, was identified in 47/207 (22.7%) patients. Increased TPX2 immunostaining was associated with poor OS (P = 0.0327, 53% 5-year mortality), cancer-specific survival (P<0.01, 47.8% 5-year cancer-specific mortality), RFS (P = 0.0313, 73.6%, 5-year recurrence rate), grade, T stage, and metastasis. Multivariate analysis demonstrated elevated expression served as an independent predictor of RFS (hazard ratio = 3.62 (1.13–11.55), P = 0.029). We show TPX2, a regulator of Aurora-A, is associated with high grade and stage of ccRCC, and is an independent predictor of recurrence. Future studies are warranted testing its role in ccRCC biology, and its potential as a therapeutic target." @default.
• W2578102513 created "2017-01-26" @default.
• W2578102513 creator A5004399207 @default.
• W2578102513 creator A5021979132 @default.
• W2578102513 creator A5024776928 @default.
• W2578102513 creator A5050663947 @default.
• W2578102513 creator A5054607683 @default.
• W2578102513 creator A5058206823 @default.
• W2578102513 creator A5061844639 @default.
• W2578102513 creator A5066279767 @default.
• W2578102513 creator A5081635691 @default.
• W2578102513 creator A5091459519 @default.
• W2578102513 date "2017-05-01" @default.
• W2578102513 modified "2023-10-17" @default.
• W2578102513 title "TPX2 as a prognostic indicator and potential therapeutic target in clear cell renal cell carcinoma" @default.
• W2578102513 cites W1967827870 @default.
• W2578102513 cites W1981424030 @default.
• W2578102513 cites W1985213644 @default.
• W2578102513 cites W1991948593 @default.
• W2578102513 cites W1994375251 @default.
• W2578102513 cites W2014057009 @default.
• W2578102513 cites W2018179071 @default.
• W2578102513 cites W2019092280 @default.
• W2578102513 cites W2023695022 @default.
• W2578102513 cites W2030940438 @default.
• W2578102513 cites W2039545078 @default.
• W2578102513 cites W2051603299 @default.
• W2578102513 cites W2077338924 @default.
• W2578102513 cites W2129946644 @default.
• W2578102513 cites W2137732261 @default.
• W2578102513 cites W2138180163 @default.
• W2578102513 cites W2148292827 @default.
• W2578102513 cites W2149441684 @default.
• W2578102513 cites W2149891163 @default.
• W2578102513 cites W2155564780 @default.
• W2578102513 cites W2170248514 @default.
• W2578102513 cites W2235523093 @default.
• W2578102513 cites W2239801579 @default.
• W2578102513 cites W2335012284 @default.
• W2578102513 cites W2520363872 @default.
• W2578102513 cites W4243827915 @default.
• W2578102513 doi "https://doi.org/10.1016/j.urolonc.2016.12.012" @default.
• W2578102513 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28108243" @default.
• W2578102513 hasPublicationYear "2017" @default.
• W2578102513 type Work @default.
• W2578102513 sameAs 2578102513 @default.
• W2578102513 citedByCount "13" @default.
• W2578102513 countsByYear W25781025132018 @default.
• W2578102513 countsByYear W25781025132019 @default.
• W2578102513 countsByYear W25781025132020 @default.
• W2578102513 countsByYear W25781025132021 @default.
• W2578102513 countsByYear W25781025132022 @default.
• W2578102513 countsByYear W25781025132023 @default.
• W2578102513 crossrefType "journal-article" @default.
• W2578102513 hasAuthorship W2578102513A5004399207 @default.
• W2578102513 hasAuthorship W2578102513A5021979132 @default.
• W2578102513 hasAuthorship W2578102513A5024776928 @default.
• W2578102513 hasAuthorship W2578102513A5050663947 @default.
• W2578102513 hasAuthorship W2578102513A5054607683 @default.
• W2578102513 hasAuthorship W2578102513A5058206823 @default.
• W2578102513 hasAuthorship W2578102513A5061844639 @default.
• W2578102513 hasAuthorship W2578102513A5066279767 @default.
• W2578102513 hasAuthorship W2578102513A5081635691 @default.
• W2578102513 hasAuthorship W2578102513A5091459519 @default.
• W2578102513 hasConcept C126322002 @default.
• W2578102513 hasConcept C143998085 @default.
• W2578102513 hasConcept C146357865 @default.
• W2578102513 hasConcept C151730666 @default.
• W2578102513 hasConcept C193270364 @default.
• W2578102513 hasConcept C204232928 @default.
• W2578102513 hasConcept C207103383 @default.
• W2578102513 hasConcept C2777472916 @default.
• W2578102513 hasConcept C2781278892 @default.
• W2578102513 hasConcept C44249647 @default.
• W2578102513 hasConcept C50382708 @default.
• W2578102513 hasConcept C71924100 @default.
• W2578102513 hasConcept C72563966 @default.
• W2578102513 hasConcept C86803240 @default.
• W2578102513 hasConceptScore W2578102513C126322002 @default.
• W2578102513 hasConceptScore W2578102513C143998085 @default.
• W2578102513 hasConceptScore W2578102513C146357865 @default.
• W2578102513 hasConceptScore W2578102513C151730666 @default.
• W2578102513 hasConceptScore W2578102513C193270364 @default.
• W2578102513 hasConceptScore W2578102513C204232928 @default.
• W2578102513 hasConceptScore W2578102513C207103383 @default.
• W2578102513 hasConceptScore W2578102513C2777472916 @default.
• W2578102513 hasConceptScore W2578102513C2781278892 @default.
• W2578102513 hasConceptScore W2578102513C44249647 @default.
• W2578102513 hasConceptScore W2578102513C50382708 @default.
• W2578102513 hasConceptScore W2578102513C71924100 @default.
• W2578102513 hasConceptScore W2578102513C72563966 @default.
• W2578102513 hasConceptScore W2578102513C86803240 @default.
• W2578102513 hasIssue "5" @default.
• W2578102513 hasLocation W25781025131 @default.
• W2578102513 hasLocation W25781025132 @default.
• W2578102513 hasOpenAccess W2578102513 @default.
• W2578102513 hasPrimaryLocation W25781025131 @default.
• W2578102513 hasRelatedWork W1529830839 @default.

• next